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Thus, the questionnaire on neuropathic pain proposed
to European neurologists by Sommer and colleagues is to
be praised for fostering awareness of neuropathic pain as
a diagnostic challenge among specialists who by tradition
have shown little interest in pain management [2]. As
acknowledged by the authors, most of the answers come
from only 4 countries, albeit with a widespread geograph-
ical, cultural and economic representation. The survey
reports surprising data, seemingly contradicting the
assumption that neurologists are not interested in pain: the
majority of the 745 respondents stated they are familiar
with neuropathic pain, 33.6% of them declared they see
neuropathic pain cases daily and 41.5% weekly.
Unfortunately, on closer scrutiny the data on the
European neurologists’ expertise in diagnosing neuropath-
ic pain are not so reassuring. The survey collected only the
responses of the neurologists willing to answer the ques-
tionnaire, a selection that obviously leads to overestimat-
ing the findings. In addition, the responses provided do not
demonstrate the claimed level of familiarity: the majority
of respondents mentioned widespread peripheral neuro-
pathic pain conditions (diabetic neuropathy, radiculopathy
and trigeminal neuralgia) that should be familiar to gener-
al practitioners, while other common neuropathic pain
conditions such as post-herpetic neuralgia and nerve
entrapment were mentioned by only one third of the
respondents. The percentage of the respondents familiar
with central pain and nerve injury pain was less than one
quarter; a quite disappointing figure for those who should
be specialists in diagnosing neuropathic pain conditions
and have a declared interest in the subject.
Given this level of information, the statement that
NSAIDS are still prescribed for treating neuropathic pain
comes as no surprise, as does the seemingly contradictory
report that antidepressants are the most used drug catego-
ry, while gabapentin is the single most used drug. (The sur-
vey was launched before the introduction of pregabalin
and duloxetine for treating neuropathic pain; at that time
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A survey on chronic pain in Europe based on a huge pop-
ulation interview available on-line since 2005 reports that
an average of 19% of adult Europeans suffer from a chron-
ic pain condition that in 40% of cases is not adequately con-
trolled [1]. More than half of the patients interviewed used
NSAIDS as the drug of choice, thus it is tempting to put
forward the hypothesis that poor pain management is due to
inadequate recognition of the cause of the pain. NSAIDS
are not the drug of choice for neuropathic pain, while this
type of pain ranks highly among the causes of chronic pain,
either as an isolated cause (peripheral neuropathies and
central pains) or jointly with osteoarthritis (cervical and
lumbar-sacral radiculopathy). Indeed, European physicians
still have a long way to go to improve chronic pain man-
agement and certainly there is room for improvement in the
proper diagnosis of neuropathic pain.
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the only effective antidepressants were the tricyclics,
while the choice of antiepileptics was slightly wider.) As
pinpointed by the authors, some of the respondents also
failed in recognising VAS and NRS among the pain scales,
an additional indirect indication that familiarity with pain
management was lower than that stated. Many neuropath-
ic pain conditions are very difficult to treat and require
comprehensive evaluation and at times even invasive ther-
apies; it is also surprising that the respondents were so
successful in achieving 75% pain relief and only 3% need-
ed to refer patients to pain clinics.
Taking all this into consideration, we do not share the
optimism of the authors of this survey on the attitude of
European neurologists toward neuropathic pain. Rather,
we believe that much more information is needed on this
subject. However, we strongly agree with the final state-
ment of Sommer and colleagues that “neurologists also
see the necessity for more education and for improvement
of the treatment of neuropathic pain” and indeed, despite
all the mentioned limitations of this study, we praise the
authors for calling attention to this neurological chal-
lenge.
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Reply from the author
We thank the correspondents for their critical praise of our
survey. Indeed, we agree with most of the points raised. By all
means the neurologists who answered our questionnaire were
a positive selection, as they were obviously interested in the
subject of neuropathic pain. Even within this motivated
group, there were some doubts on the use of standardised pain
scales, thus neurologists do need more education in this field.
One point was misunderstood by Marchettini and Solaro. We
did not ask whether the physicians were familiar with diabet-
ic neuropathy, central pain and so on; we asked them which
were the most frequently seen diagnoses. This explains why
the comparatively rarer conditions, such as central neuropath-
ic pain, were mentioned by fewer participants. The reason
was not that they were unfamiliar with central pain.
The interest in our results has motivated us to engage in a
new survey with an improved strategy to avoid bias and also
an improved set of questions. We are confident that actions
like this will increase the awareness of this challenging part
of neurology and will hopefully, in the long run, improve
patient management.
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